Soleno Therapeutics Faces Securities Fraud Lawsuit Over Alleged Sham Phase 3 Clinical Trials

Key Takeaways

• Soleno Therapeutics faces securities fraud lawsuit alleging the company conducted sham Phase 3 clinical trials
• FDA drug approval reportedly based entirely on potentially fraudulent 16-week randomized withdrawal study
• Class action lawsuit seeks lead plaintiffs among investors who suffered losses from alleged securities violations

---

Soleno Therapeutics, Inc. (NASDAQ: SLNO) is facing serious securities fraud allegations in a class action lawsuit that claims the biotechnology company conducted fraudulent Phase 3 clinical trials to secure FDA approval for its drug candidate.

Fraud Allegations Center on Pivotal Clinical Trial

The lawsuit, announced by law firm Levi & Korsinsky, alleges that Soleno’s FDA drug approval was built on deceptive clinical trial data. According to the complaint, the regulatory approval rested entirely on the company’s Phase 3 clinical trial program, including what investigators claim was a fraudulent 16-week randomized withdrawal study.

The allegations suggest that Soleno may have manipulated or misrepresented critical safety and efficacy data during the pivotal trial phase, potentially misleading both regulators and investors about the true performance of their drug candidate.

IntelligenceRegulatory Impact▾

NMPA, PMDA, and TGA are the agencies to watch. Regulatory relevance reads medium for unknown. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Market Impact and Investor Losses

The securities fraud lawsuit comes as investors who purchased Soleno shares allegedly suffered significant financial losses following revelations about the clinical trial conduct. The legal action seeks to identify lead plaintiffs among affected shareholders who can demonstrate substantial damages from the alleged securities violations.

Soleno’s stock price and market valuation could face continued pressure as the legal proceedings unfold and regulatory authorities potentially review the underlying clinical data that supported the original FDA approval decision.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Regulatory Implications

If the fraud allegations prove substantiated, Soleno could face severe consequences including:

• FDA Investigation: Regulatory authorities may launch a comprehensive review of all submitted clinical data
• Approval Withdrawal: The FDA could potentially revoke drug approval if trials are found to be fraudulent
• Criminal Referral: Serious clinical trial fraud can result in criminal charges against company executives
• Financial Penalties: Both SEC and FDA enforcement actions could result in substantial monetary penalties

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for unknown pricing, access, and launch sequencing.

Industry-Wide Concerns

The Soleno case highlights ongoing concerns about clinical trial integrity in the biotechnology sector. Fraudulent trial conduct not only harms investors but potentially puts patients at risk by bringing ineffective or unsafe treatments to market based on falsified data.

Regulatory experts note that the FDA’s approval process relies heavily on the integrity of sponsor-conducted clinical trials, making accurate data reporting essential for patient safety and market confidence.

IntelligenceStrategic Takeaways▾

Soleno Therapeutics faces securities fraud lawsuit alleging the company conducted sham Phase 3 clinical trials FDA drug approval reportedly based entirely on potentially fraudulent 16-week randomized withdrawal study Class action lawsuit seeks lead plaintiffs among investors who suffered losses from alleged securities violations

Legal Proceedings Timeline

The class action lawsuit is currently in its early stages, with Levi & Korsinsky seeking qualified lead plaintiffs who can effectively represent the interests of all affected shareholders. Investors who purchased Soleno securities during the relevant period and suffered losses may be eligible to participate in the legal action.

The litigation process could extend over several years, particularly if regulatory investigations run parallel to the securities fraud case. Settlement discussions or trial proceedings will likely depend on the strength of evidence regarding the alleged clinical trial misconduct.

IntelligenceEvidence Quality▾

Claims are grounded in the cited primary and secondary sources, with editorial review applied before publication.

Company Response

Soleno Therapeutics has not yet issued a public response to the specific fraud allegations outlined in the class action complaint. The company’s legal and regulatory teams will likely need to address both the securities lawsuit and any potential FDA inquiries regarding clinical trial conduct.

Investors and industry observers will be closely monitoring Soleno’s response strategy and any additional disclosures about the disputed Phase 3 trial data that formed the basis for FDA approval.

---

Frequently Asked Questions

What does this lawsuit mean for patients using Soleno’s approved drug?

Patients should continue following their prescribed treatment regimen while monitoring for FDA updates. If clinical trial fraud is confirmed, the FDA may review the drug’s safety and efficacy profile and potentially modify or withdraw approval.

How can Soleno investors participate in the class action lawsuit?

Investors who purchased Soleno securities during the relevant period and suffered losses can contact Levi & Korsinsky or other qualified securities law firms to explore participation in the class action and potentially serve as lead plaintiffs.

What happens if the FDA finds the clinical trials were fraudulent?

If fraud is confirmed, the FDA could withdraw drug approval, require new clinical trials, impose restrictions on the company’s operations, or refer the matter for criminal prosecution of responsible executives.

Related coverage

• Onconic Therapeutics' Jakubo Enters Phase 3 Clinical Trials in China
• Clinical Trials Outsourcing Market Size: 2026-2034 Growth Outlook
• Nektar Therapeutics pipeline update: REZPEG clinical programs and regulatory context